| Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma SP Patel, M Othus, Y Chen, GP Wright Jr, KJ Yost, JR Hyngstrom, ... New England Journal of Medicine 388 (9), 813-823, 2023 | 291 | 2023 |
| NCCN guidelines insights: bone cancer, version 2.2017 JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ... Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 2017 | 271 | 2017 |
| Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain KW Staver, RB Brinsfield Journal of Soil and Water Conservation 53 (3), 230-240, 1998 | 258 | 1998 |
| Anti-HIV drugs for cancer therapeutics: back to the future? WA Chow, C Jiang, M Guan The lancet oncology 10 (1), 61-71, 2009 | 227 | 2009 |
| First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies GJ Weiss, J Chao, JD Neidhart, RK Ramanathan, D Bassett, JA Neidhart, ... Investigational new drugs 31, 986-1000, 2013 | 217 | 2013 |
| A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma … AS Pappo, G Vassal, JJ Crowley, V Bolejack, PCW Hogendoorn, ... Cancer 120 (16), 2448-2456, 2014 | 197 | 2014 |
| Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology HJ Burstein, L Krilov, JB Aragon-Ching, NN Baxter, EG Chiorean, ... Journal of Clinical Oncology 35 (12), 1341-1367, 2017 | 149 | 2017 |
| A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on … HC Fung, A Stein, ML Slovak, MR O’donnell, DS Snyder, S Cohen, ... Biology of Blood and Marrow Transplantation 9 (12), 766-771, 2003 | 148 | 2003 |
| Bone cancer JS Biermann, DR Adkins, M Agulnik, RS Benjamin, B Brigman, ... Journal of the National Comprehensive Cancer Network 11 (6), 688-723, 2013 | 136 | 2013 |
| Chondrosarcoma: biology, genetics, and epigenetics WA Chow F1000Research 7, 2018 | 135 | 2018 |
| Update on chondrosarcomas WA Chow Current opinion in oncology 19 (4), 371-376, 2007 | 127 | 2007 |
| The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells WA Chow, JJ Fang, JK Yee The Journal of Immunology 164 (7), 3512-3518, 2000 | 126 | 2000 |
| Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma: international index high … A Nademanee, A Molina, MR O'Donnell, A Dagis, DS Snyder, P Parker, ... Blood, The Journal of the American Society of Hematology 90 (10), 3844-3852, 1997 | 122 | 1997 |
| Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma I Ramachandran, DE Lowther, R Dryer-Minnerly, R Wang, S Fayngerts, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 120 | 2019 |
| Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor SM Schuetze, V Bolejack, E Choy, KN Ganjoo, AP Staddon, WA Chow, ... Cancer 123 (1), 90-97, 2017 | 120 | 2017 |
| Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral … G Somlo, I Sniecinski, A Ter Veer, J Longmate, G Knutson, S Vuk-Pavlovic, ... Blood, The Journal of the American Society of Hematology 93 (9), 2798-2806, 1999 | 113 | 1999 |
| Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma K Zhang, K Chu, X Wu, H Gao, J Wang, YC Yuan, S Loera, K Ho, Y Wang, ... Cancer research 73 (4), 1298-1307, 2013 | 112 | 2013 |
| SARC009: phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma SM Schuetze, JK Wathen, DR Lucas, E Choy, BL Samuels, AP Staddon, ... Cancer 122 (6), 868-874, 2016 | 104 | 2016 |
| Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University … L Wiebe, KE Kasza, RG Maki, DR D’Adamo, WA Chow, JL Wade III, ... Journal of Clinical Oncology 26 (15_suppl), 10502-10502, 2008 | 94 | 2008 |
| A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). JC Trent, K Wathen, M Von Mehren, BL Samuels, AP Staddon, E Choy, ... Journal of Clinical Oncology 29 (15_suppl), 10006-10006, 2011 | 91 | 2011 |
